0
Allergy and Airway: Asthma I |

Omalizumab Improves Asthma Symptoms, Asthma Control, and Health-Related Quality of Life in Chinese Patients With Moderate-to-Severe Asthma

Jing Li, MD; Jian Kang; Changzheng Wang, MD; Jing Yang, PhD; Michael Humphries, MD; Steven Greenberg, MD; Nanshan Zhong, MD
Author and Funding Information

State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A6. doi:10.1016/j.chest.2016.02.008
Text Size: A A A
Published online

Extract

SESSION TITLE: Asthma I

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Omalizumab (OMA), a humanized monoclonal anti-IgE antibody, is recommended by the GINA guidelines as a step 5 therapy for the treatment of persistent moderate-to-severe allergic asthma. However, there is limited data on the management of Chinese patients (pts) with OMA. We report here the effect of OMA on asthma and symptom control, use of rescue medication and quality of life (QOL) in Chinese pts with moderate-to-severe allergic asthma.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Omalizumab for severe persistent allergic asthma.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543